Investigating forthcoming strategies to tackle deadly superbugs: current status and future vision

References

• Uddin TM, Chakraborty AJ, Khusro A, et al. Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects. J Infect Public Health. 2021;14(12):1750–1766.
   PubMed Web of Science ®Google Scholar
• Ferri M, Ranucci E, Romagnoli P, et al. Antimicrobial resistance: a global emerging threat to public health systems. Crit Rev Food Sci Nutr. 2017;57(13):2857–2876.
   PubMed Web of Science ®Google Scholar
• Mehta AC, Muscarella LF. Bronchoscope-related “superbug. Infections Chest. 2020;157(2):454–469.
   PubMed Web of Science ®Google Scholar
• Ma Z, Lee S, Casey Jeong K. Mitigating antibiotic resistance at the livestock-environment interface: a review. J Microbiol Biotechnol. 2019;29(11):1683–1692.
   PubMed Web of Science ®Google Scholar
• Dweba CC, Zishiri OT, El Zowalaty ME. Methicillin-resistant staphylococcus aureus: livestock-associated, antimicrobial, and heavy metal resistance. Infect Drug Resist. 2018;11:2497–2509.
   PubMed Web of Science ®Google Scholar
• Simren D, Yordanova R. New hope for dealing with “superbugs. Trakia J Sci. 2020;18(Suppl.1):122–124.
   Google Scholar
• Yin X, Hamasaki T, Follmann D, et al. OutSMARTing superbugs. Chance. 2020;33(3):22–30.
   Google Scholar
• Alharthi S, Alavi SE, Moyle PM, et al. Sortase A (SrtA) inhibitors as an alternative treatment for superbug infections. Drug Discov Today. 2021;26(9):2164–2172.
   PubMed Web of Science ®Google Scholar
• Hossain MA. Evolution of superbugs: a lethal bioterror. Brac University; 2019.
   Google Scholar
• Yam ELY, Hsu LY, Yap EPH, et al. Antimicrobial resistance in the Asia Pacific region: a meeting report. Antimicrob Resist Infect Control. 2019;8(1):1–12.
   PubMed Web of Science ®Google Scholar
• Levy DD, Sharma B, Cebula TA. Single-nucleotide polymorphism mutation spectra and resistance to quinolones in Salmonella enterica serovar enteritidis with a mutator phenotype. Antimicrob Agents Chemother. 2004;48(7):2355–2363.
   PubMed Web of Science ®Google Scholar
• Dramé O, Leclair D, Parmley EJ, et al. Antimicrobial resistance of campylobacter in broiler chicken along the food chain in Canada. Foodborne Pathog Dis. 2020;17(8):512–520.
   PubMed Web of Science ®Google Scholar
• Organization WH. New report calls for urgent action to avert antimicrobial resistance crisis. Jt News Release. 2019;29:2019–2022.
   Google Scholar
• Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655.
   PubMed Web of Science ®Google Scholar
• GLOBAL TUBERCULOSIS REPORT 2018. 2018.
   Google Scholar
• Lim C, Takahashi E, Hongsuwan M, et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. Elife. 2016;5. DOI:10.7554/eLife.18082.
   Web of Science ®Google Scholar
• Kaur S, Sneha Hariharan SD. Superbugs: the powerful warriors. Int J Pharm Sci Res. 2020;11:1506–1526.
   Web of Science ®Google Scholar
• Global Antimicrobial Resistance and Use Surveillance System (GLASS) report: 2021.
   Google Scholar
• Domingues CPF, Rebelo JS, Pothier J, et al. The perfect condition for the rising of superbugs: person-to-person contact and antibiotic use are the key factors responsible for the positive correlation between antibiotic resistance gene diversity and virulence gene diversity in human metagenomes. Antibiotics. 2021;10(5):605.
   Google Scholar
• John WP. Defeating pathogen drug resistance: guidance from evolutionary theory. Evolution. 2008;62(12):3185–3191.
   PubMed Web of Science ®Google Scholar
• Dykhuizen D. Species numbers in bacteria. Proc Calif Acad Sci. 2005;56(6 Suppl 1):62–71.
   PubMedGoogle Scholar
• Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health Maney Publishing. 2015;109(7):309–318.
   PubMed Web of Science ®Google Scholar
• Kapil A. The challenge of antibiotic resistance: need to contemplate. Ind J Med Res. 2005;121(2):83–91.
   PubMed Web of Science ®Google Scholar
• Bansal R, Jain A, Goyal M, et al. Antibiotic abuse during endodontic treatment: a contributing factor to antibiotic resistance. J Fam Med Prim Care. 2019;8(11):3518.
   PubMedGoogle Scholar
• Ramachandran P, Rachuri N, Martha S, et al. Implications of overprescription of antibiotics: a cross-sectional study. J Pharm Bioallied Sci. 2019;11(6):S434–S437.
   PubMedGoogle Scholar
• Konde S, Jairam LS, Peethambar P, et al. Antibiotic overusage and resistance: a cross-sectional survey among pediatric dentists. J Indian Soc Pedod Prev Dent. 2016;34(2):145–151.
   PubMedGoogle Scholar
• Johansen TB, Scheffer L, Jensen VK, et al. Whole-genome sequencing and antimicrobial resistance in Brucella melitensis from a Norwegian perspective. Sci Rep. 2018;8(1):8538.
   PubMedGoogle Scholar
• Nepal G, Bhatta S. Self-medication with antibiotics in WHO Southeast Asian Region: a systematic review. Cureus. 2018;10.
   Web of Science ®Google Scholar
• Karakonstantis S, Kalemaki D. Antimicrobial overuse and misuse in the community in Greece and link to antimicrobial resistance using methicillin-resistant S. aureus as an example. J Infect Public Health Elsevier Ltd. 2019;12(4):460–464.
   PubMed Web of Science ®Google Scholar
• Zawahir S, Lekamwasam S, Aslani P. A cross-sectional national survey of community pharmacy staff: knowledge and antibiotic provision. PLoS One. 2019;14.
   Google Scholar
• Bengtsson B, Greko C. Antibiotic resistance-consequences for animal health, welfare, and food production. Ups J Med Sci Informa Healthcare. 2014;119(2):96–102.
   PubMed Web of Science ®Google Scholar
• Manyi-Loh C, Mamphweli S, Meyer E, et al. Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. Molecules MDPI AG. 2018;23(4):795.
   PubMed Web of Science ®Google Scholar
• Shi X, Wang S. Antibiotic resistance in environment of animal farms. Shengwu Gongcheng Xuebao/Chinese J Biotechnol. 2018;34:1234–1245.
   PubMedGoogle Scholar
• Lindsay JA. Hospital-associated MRSA and antibiotic resistance-what have we learned from genomics? Int J Med Microbiol Urban & Fischer. 2013;303(6–7):318–323.
   PubMed Web of Science ®Google Scholar
• Morris A, Kellner JD, Low DE. The superbugs: evolution, dissemination and fitness. Curr Opin Microbiol. 1998;1(5):524–529.
   PubMed Web of Science ®Google Scholar
• Progress on wastewater treatment. 2021 UN-Water.
   Google Scholar
• Sano D, Wester AL, Schmitt H, et al. Updated research agenda for water, sanitation and antimicrobial resistance. J Water Health. 2020;18(6):858–866.
   PubMed Web of Science ®Google Scholar
• Collignon P, Beggs JJ, Walsh TR, et al. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. Lancet Planet Heal. 2018;2(9):e398–e405.
   PubMedGoogle Scholar
• Andremont A, Walsh T. The role of sanitation in the development and spread of antimicrobial resistance. Glob Heal Dyn. 2015;67: 68–73
   Google Scholar
• Ramay BM, Caudell MA, Cordón-Rosales C, et al. Antibiotic use and hygiene interact to influence the distribution of antimicrobial-resistant bacteria in low-income communities in Guatemala. Sci Rep. 2020;10(1):1–10.
   PubMed Web of Science ®Google Scholar
• Musoke D, Namata C, Lubega GB, et al. The role of environmental health in preventing antimicrobial resistance in low- and middle-income countries. Environ Health Prev Med. 2021;26(1):4–9.
   PubMed Web of Science ®Google Scholar
• Hobman JL, Crossman LC. Bacterial antimicrobial metal ion resistance. J Med Microbiol Microbiology Society. 2015;64(5):471–497.
   PubMed Web of Science ®Google Scholar
• Jacob ME, Fox JT, Nagaraja TG, et al. Effects of feeding elevated concentrations of copper and zinc on the antimicrobial susceptibilities of fecal bacteria in feedlot cattle. Foodborne Pathog Dis. 2010;7(6):643–648.
   PubMed Web of Science ®Google Scholar
• Knapp CW, McCluskey SM, Singh BK, et al. Antibiotic resistance gene abundances correlate with metal and geochemical conditions in archived Scottish soils. PLoS One. 2011;6(11):27300.
   PubMed Web of Science ®Google Scholar
• Watkins RR, Bonomo RA. Overview: global and local impact of antibiotic resistance. Infect Dis Clin North Am. 2016;30(2):313–322.
   PubMed Web of Science ®Google Scholar
• Chang Q, Wang W, Regev-Yochay G, et al. Antibiotics in agriculture and the risk to human health: how worried should we be? Evol Appl. 2015;8(3):240–247.
   PubMed Web of Science ®Google Scholar
• COM. A European one health action plan against antimicrobial resistance (AMR). Brussels, Belgium: European Commission; 2017. https://ec.europa.eu/health/antimicrobial-resistance/eu-action-on-antimicrobial-resistance_es
   Google Scholar
• Wells V, Piddock LJV. Addressing antimicrobial resistance in the UK and Europe. Lancet Infect Dis. 2017;17(12):1230–1231.
   PubMed Web of Science ®Google Scholar
• Ntt D, Ntd T, Tran NTH, et al. Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary health care: a randomised controlled trial. Lancet Glob Heal. 2016;4(9):e633–e641.
   PubMed Web of Science ®Google Scholar
• Liz Szabo, Kaiser Health News, Digital Access to Scientific American. “Nightmare bacteria” widespread in U.S. Springer Nature, USA: Hospitals - Scientific American 2018.
   Google Scholar
• Gulumbe B. Despite huge investment to contain AMR, recent reports of increased occurrence of superbugs are terrifying. Sri Lankan J Infect Dis. 2018;8(2):69.
   Google Scholar
• Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship programs from the centers for disease control and prevention. Clin Infect Dis. 2014;59(suppl_3):S97–S100.
   PubMedGoogle Scholar
• Valiullina ZR, Galeeva AM, Gimalova FA, et al. Synthesis and in vitro antibacterial activity of new C-3-modified carbapenems. Russ J Bioorganic Chem. 2019;45(5):398–404.
   Web of Science ®Google Scholar
• Raza A, Ngieng SC, Sime FB, et al. Oral meropenem for superbugs: challenges and opportunities. Drug Discov Today. 2021;26(2):551–560.
   PubMed Web of Science ®Google Scholar
• Lederberg J. Smaller fleas … ad infinitum: therapeutic bacteriophage redux. Proc Natl Acad Sci U S A. 1996;93(8):3167.
   PubMed Web of Science ®Google Scholar
• Marcuk LM, Nikiforov VN, Scerbak JF, et al. Clinical studies of the use of bacteriophage in the treatment of cholera. Bull World Health Organ. 1971;45(1):77.
   PubMed Web of Science ®Google Scholar
• Jacobs-Sera D, Marinelli LJ, Bowman C, et al. On the nature of mycobacteriophage diversity and host preference. Virology. 2012;434(2):187–201.
   PubMed Web of Science ®Google Scholar
• Shahraki AH, Mirsaeidi M. Phage therapy for mycobacterium abscessus and strategies to improve outcomes. Microorganisms. 2021;9:1–20.
   Web of Science ®Google Scholar
• Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111–114.
   PubMedGoogle Scholar
• Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25(5):730–733.
   PubMed Web of Science ®Google Scholar
• Baral B, Mozafari MR. Strategic moves of “superbugs” against available chemical scaffolds: signaling, regulation, and challenges. ACS Pharmacol Transl Sci. 2020;3(3):373–400.
   PubMedGoogle Scholar
• Murteira S, Millier A, Ghezaiel Z, et al. Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications. J Mark Access Heal Policy. 2014;2(1):22813.
   PubMedGoogle Scholar
• Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018;18(1):41–58.
   PubMed Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–683.
   PubMed Web of Science ®Google Scholar
• De Oliveira HC, Monteiro MC, Rossi SA, et al. Identification of off-patent compounds that present antifungal activity against the emerging fungal pathogen Candida auris. Front Cell Infect Microbiol. 2019;9:83.
   PubMed Web of Science ®Google Scholar
• González-Bello C. Antibiotic adjuvants - A strategy to unlock bacterial resistance to antibiotics. Bioorg Med Chem Lett. 2017;27(18):4221–4228.
   PubMed Web of Science ®Google Scholar
• Billamboz M, Fatima Z, Hameed S, et al. Promising drug candidates and new strategies for fighting against the emerging superbug candida auris. Microorganisms. 2021;9(3):1–39.
   Web of Science ®Google Scholar
• Drlica K, Malik M, Kerns RJ, et al. Quinolone-mediated bacterial death. Antimicrob Agents Chemother. 2008;52(2):385–392.
   PubMed Web of Science ®Google Scholar
• Gray DA, Wenzel M. Multitarget approaches against multiresistant superbugs. ACS Infect Dis. 2020;6(6):1346–1365.
   PubMed Web of Science ®Google Scholar
• Schneider EK, Reyes-Ortega F, Velkov T, et al. Antibiotic-non-antibiotic combinations for combating extremely drug-resistant gram-negative “superbugs. Essays Biochem. 2017;61(1):115–125.
   PubMed Web of Science ®Google Scholar
• Pericas JM, Cervera C, Del Rio A, et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect. 2014;20(12):O1075–O1083.
   PubMed Web of Science ®Google Scholar
• Fiore M, Maraolo AE, Gentile I, et al. Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis. World J Hepatol. 2017;9(30):1166–1175.
   PubMed Web of Science ®Google Scholar
• Sharifi-Rad J. Herbal antibiotics: moving back into the mainstream as an alternative for “superbugs. Cell Mol Biol. 2016;62(9):1–2.
   PubMed Web of Science ®Google Scholar
• Draenert R, Seybold U, Grützner E, et al. Novel antibiotics: are we still in the pre–post-antibiotic era? Infection. Infection. 2015;43(2):145–151.
   PubMed Web of Science ®Google Scholar
• Dwivedi GR, Tyagi R, Sanchita, et al. Antibiotics potentiating potential of catharanthine against superbug Pseudomonas aeruginosa. J Biomol Struct Dyn. 2018;36(16):4270–4284.
   PubMed Web of Science ®Google Scholar
• Liang CH, Romero A, Rabuka D, et al. Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. Bioorganic Med Chem Lett. 2005;15(8):2123–2128.
   PubMed Web of Science ®Google Scholar
• Hamilton-miller JMT. Dual-action antibiotic hybrids. J Antimicrob Chemother. 1994;33(2):197–200.
   PubMed Web of Science ®Google Scholar
• Yang X, Ammeter D, Idowu T, et al. Amphiphilic nebramine-based hybrids rescue legacy antibiotics from intrinsic resistance in multidrug-resistant gram-negative bacilli. Eur J Med Chem. 2019;175:187–200.
   PubMed Web of Science ®Google Scholar
• Ma Z, Lynch AS. Development of a dual-acting antibacterial agent (TNP-2092) for the Treatment of persistent bacterial infections. J Med Chem. 2016;59(14):6645–6657.
   PubMed Web of Science ®Google Scholar
• Robertson GT, Bonventre EJ, Doyle TB, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52(7):2313–2323.
   PubMed Web of Science ®Google Scholar
• Reid G, Dhir R. Probiotics: reiterating what they are and what they are not. Front Microbiol. 2019;10. DOI:10.3389/fmicb.2019.00424
   Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, et al. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514.
   PubMed Web of Science ®Google Scholar
• Davani-Davari D, Negahdaripour M, Karimzadeh I, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods. 2019;8(3):1–27.
   Web of Science ®Google Scholar
• Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011;9(2):88–96.
   PubMed Web of Science ®Google Scholar
• Isolauri E, Salminen S, Ouwehand AC. Microbial-gut interactions in health and disease. Probiotics Best Pract Res Clin Gastroenterol. 2004;18(2):299–313.
   PubMed Web of Science ®Google Scholar
• Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500–508.
   PubMed Web of Science ®Google Scholar
• Nagpal R, Kumar A, Kumar M, et al. Probiotics, their health benefits and applications for developing healthier foods: a review. FEMS Microbiol Lett. 2012;334(1):1–15.
   PubMed Web of Science ®Google Scholar
• Miller KP, Wang L, Benicewicz BC, et al. Inorganic nanoparticles engineered to attack bacteria. Chem Soc Rev. 2015;44(21):7787–7807.
   PubMed Web of Science ®Google Scholar
• Fang G, Li W, Shen X, et al. Differential Pd-nanocrystal facets demonstrate distinct antibacterial activity against gram-positive and gram-negative bacteria. Nat Commun. 2018;9(1). DOI:10.1038/s41467-017-02502-3.
   Google Scholar
• Zheng Y, Liu W, Qin Z, et al. Mercaptopyrimidine-conjugated gold nanoclusters as nanoantibiotics for combating multidrug-resistant superbugs. Bioconjug Chem. 2018;29(9):3094–3103.
   PubMed Web of Science ®Google Scholar
• Ahmady IM, Hameed MK, Almehdi AM, et al. Green and cytocompatible carboxyl modified gold-lysozyme nanoantibacterial for combating multidrug-resistant superbugs. Biomater Sci. 2019;7(12):5016–5026.
   PubMed Web of Science ®Google Scholar
• Yang X, Yang J, Wang L, et al. Pharmaceutical intermediate-modified gold nanoparticles: against multidrug-resistant bacteria and wound-healing application via an electrospun scaffold. ACS Nano. 2017;11(6):5737–5745.
   PubMed Web of Science ®Google Scholar
• Zheng K, Setyawati MI, Leong DT, et al. Antimicrobial gold nanoclusters. ACS Nano. 2017;11(7):6904–6910.
   PubMed Web of Science ®Google Scholar
• V WJ, Cheeseman S, Truong VK, et al. Outsmarting superbugs: bactericidal activity of nanostructured titanium surfaces against methicillin- and gentamicin-resistant Staphylococcus aureus ATCC 33592. J Mater Chem B. 2019;7(28):4424–4431.
   Web of Science ®Google Scholar
• Richter K, Facal P, Thomas N, et al. Taking the silver bullet colloidal silver particles for the topical treatment of biofilm-related Infections. ACS Appl Mater Interfaces. 2017;9(26):21631–21638.
   PubMed Web of Science ®Google Scholar
• Munguia J, Nizet V. Pharmacological targeting of the host–pathogen interaction: alternatives to classical antibiotics to combat drug-resistant superbugs. Trends Pharmacol Sci. 2017;38(5):473–488.
   PubMed Web of Science ®Google Scholar
• Richter K. Tackling superbugs in their slime castles: innovative approaches against antimicrobial-resistant biofilm infections. Microbiol Aust. 2019;40:165–168.
   Web of Science ®Google Scholar
• Miller MB, Bassler BL. Quorum sensing in bacteria. Annu Rev Microbiol. 2001;55(1):165–199.
   PubMed Web of Science ®Google Scholar
• Brackman G, Breyne K, De Rycke R, et al. The quorum sensing inhibitor hamamelitannin increases antibiotic susceptibility of staphylococcus aureus biofilms by affecting peptidoglycan biosynthesis and eDNA Release. Sci Rep. 2016;6(1):6.
   PubMedGoogle Scholar
• Parrino B, Schillaci D, Carnevale I, et al. Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance. Eur J Med Chem. 2019;161:154–178.
   PubMed Web of Science ®Google Scholar
• Cascioferro S, Carbone D, Parrino B, et al. Therapeutic strategies to counteract antibiotic resistance in MRSA biofilm-associated infections. ChemMedChem. 2021;16(1):65–80.
   PubMed Web of Science ®Google Scholar
• Zrelovs N, Kurbatska V, Rudevica Z, et al. Sorting out the superbugs: potential of sortase a inhibitors among other antimicrobial strategies to tackle the problem of antibiotic resistance. Antibiotics. 2021;10(2):1–14.
   Google Scholar
• Kourtesi C, Ball AR, Huang -Y-Y, et al. Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol J. 2013;7(1):34–52.
   PubMedGoogle Scholar
• Darzynkiewicz ZM, Green AT, Abdali N, et al. Identification of binding sites for efflux pump inhibitors of the AcrAB-TolC component AcrA. Biophys J. 2019;116(4):648–658.
   PubMed Web of Science ®Google Scholar
• Zechini B, Versace I. Inhibitors of multidrug resistant Efflux systems in Bacteria. Recent Pat Antiinfect Drug Discov. 2009;4(1):37–50.
   PubMedGoogle Scholar
• Li X-Z, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in gram-negative bacteria. Clin Microbiol Rev. 2015;28(2):337–418.
   PubMed Web of Science ®Google Scholar
• Singh R, Swick MC, Ledesma KR, et al. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother. 2012;56(4):1680–1685.
   PubMed Web of Science ®Google Scholar
• Nishino K, Latifi T, Groisman EA. Virulence and drug resistance roles of multidrug efflux systems of Salmonella enterica serovar Typhimurium. Mol Microbiol. 2006;59(1):126–141.
   PubMed Web of Science ®Google Scholar
• Kvist M, Hancock V, Klemm P. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl Environ Microbiol. 2008;74(23):7376–7382.
   PubMed Web of Science ®Google Scholar
• Renau TE, Léger R, Filonova L, et al. Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorganic Med Chem Lett. 2003;13(16):2755–2758.
   PubMed Web of Science ®Google Scholar
• Renau TE, Léger R, Flamme EM, et al. Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorganic Med Chem Lett. 2001;11(5):663–667.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic - A vision for applied use. Biochem Pharmacol. 2006;71(7):910–918.
   PubMed Web of Science ®Google Scholar
• Yoshida KI, Nakayama K, Kuru N, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 5: carbon-substituted analogues at the C-2 position. Bioorg Med Chem. 2006;14(6):1993–2004.
   PubMed Web of Science ®Google Scholar
• Opperman TJ, Kwasny SM, Kim HS, et al. Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob Agents Chemother. 2014;58(2):722–733.
   PubMed Web of Science ®Google Scholar
• Pos KM. Drug transport mechanism of the AcrB efflux pump. Biochim Biophys Acta - Proteins Proteomics. 2009;1794(5):782–793.
   PubMed Web of Science ®Google Scholar
• Murakami S, Nakashima R, Yamashita E, et al. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature. 2006;443(7108):173–179.
   PubMed Web of Science ®Google Scholar
• Seeger MA, Von Ballmoos C, Eicher T, et al. Engineered disulfide bonds support the functional rotation mechanism of multidrug efflux pump AcrB. Nat Struct Mol Biol. 2008;15(2):199–205.
   PubMed Web of Science ®Google Scholar
• Seeger MA, Von Ballmoos C, Verrey F, et al. Crucial role of Asp408 in the proton translocation pathway of multidrug transporter AcrB: evidence from site-directed mutagenesis and carbodiimide labeling. Biochemistry. 2009;48(25):5801–5812.
   PubMed Web of Science ®Google Scholar
• French S, Farha M, Ellis MJ, et al. Potentiation of antibiotics against gram-negative bacteria by polymyxin B analogue SPR741 from unique perturbation of the outer membrane. ACS Infect Dis. 2020;6(6):1405–1412.
   PubMed Web of Science ®Google Scholar
• Klobucar K, Côté JP, French S, et al. Chemical screen for vancomycin antagonism uncovers probes of the gram-negative outer membrane. ACS Chem Biol. 2021;16(5):929–942.
   PubMed Web of Science ®Google Scholar
• Membrane O, Overcomes D. Outer membrane disruption overcomes intrinsic, acquired, and spontaneous antibiotic resistance. MBio. 2020;11:1–15.
   Web of Science ®Google Scholar
• Burt S. Essential oils: their antibacterial properties and potential applications in foods—a review. Int J Food Microbiol. 2004;94(3):223–253.
   PubMed Web of Science ®Google Scholar
• Ultee A, Smid EJ. Influence of carvacrol on growth and toxin production by Bacillus cereus. Int J Food Microbiol. 2001;64(3):373–378.
   PubMed Web of Science ®Google Scholar
• Lahmar A, Bedoui A, Mokdad-Bzeouich I, et al. Reversal of resistance in bacteria underlies synergistic effect of essential oils with conventional antibiotics. Microb Pathog. 2017;106:50–59.
   PubMed Web of Science ®Google Scholar
• Moon SE, Kim HY, Cha JD. Synergistic effect between clove oil and its major compounds and antibiotics against oral bacteria. Arch Oral Biol. 2011;56(9):907–916.
   PubMed Web of Science ®Google Scholar
• Zhang D, Hu H, Rao Q, et al. Synergistic effects and physiological responses of selected bacterial isolates from animal feed to four natural antimicrobials and two antibiotics. Foodborne Pathog Dis. 2011;8(10):1055–1062.
   PubMed Web of Science ®Google Scholar
• Coutinho HDM, Costa JGM, Falcão-Silva VS, et al. Effect of Momordica charantia L. in the resistance to aminoglycosides in methicilin-resistant Staphylococcus aureus. Comp Immunol Microbiol Infect Dis. 2010;33(6):467–471.
   PubMed Web of Science ®Google Scholar
• Mishra B, Reiling S, Zarena D, et al. Host defense antimicrobial peptides as antibiotics: design and application strategies. Curr Opin Chem Biol. 2017;38:87–96.
   PubMed Web of Science ®Google Scholar
• Masuda R, Kudo M, Dazai Y, et al. Collagen-like antimicrobial peptides. Biopolymers. 2016;106(4):453–459.
   PubMed Web of Science ®Google Scholar
• Krizsan A, Prahl C, Goldbach T, et al. Short proline-rich antimicrobial peptides inhibit either the bacterial 70S ribosome or the assembly of its large 50S subunit. ChemBioChem. 2015;16(16):2304–2308.
   PubMed Web of Science ®Google Scholar
• Siddiqui R, Khan NA. Strategies to counter transmission of “superbugs” by targeting free-living amoebae. Exp Parasitol. 2017;183:133–136.
   PubMed Web of Science ®Google Scholar
• Carr A, Schultz J. Prospective evaluation of the incidence of wound infection in rattlesnake envenomation in dogs. J Vet Emerg Crit Care (San Antonio). 2015;25(4):546–551.
   PubMed Web of Science ®Google Scholar
• Pérez-Peinado C, Defaus S, Andreu D. Hitchhiking with nature: snake venom peptides to fight cancer and superbugs. Toxins (Basel). 2020;12(4):1–23.
   Web of Science ®Google Scholar
• Adegoke AA, Faleye AC, Singh G, et al. Antibiotic resistant superbugs: assessment of the interrelationship of occurrence in clinical settings and environmental niches. Molecules. 2017;22(1):29.
   PubMed Web of Science ®Google Scholar
• Becker K, Schaumburg F, Fegeler C, et al. Staphylococcus aureus from the German general population is highly diverse. Int J Med Microbiol. 2017;307(1):21–27.
   PubMed Web of Science ®Google Scholar
• Lee AS, de Lencastre H, Garau J, et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Prim. 2018;4:1–23.
   PubMed Web of Science ®Google Scholar
• Dzintars K, Grayson MK. The Use of antibiotics. Boca Raton, Florida, USA: CRC Press; 2018.
   Google Scholar
• Chambers FD HF. Waves of resistance: staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629–641.
   PubMed Web of Science ®Google Scholar
• Fridkin S. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436–1444.
   PubMed Web of Science ®Google Scholar
• Aguado JM, San-Juan R, Lalueza A, et al. High vancomycin MIC and complicated methicillin-susceptible staphylococcus aureus bacteremia. Emerg Infect Dis. 2011;17:1099–1102.
   PubMed Web of Science ®Google Scholar
• on behalf of the Joint Working Party of the British Society for Antimicrobial Chemotherapy HIS and ICNA: Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother. 2006;57:589–608. DOI:10.1093/jac/dkl017
   PubMed Web of Science ®Google Scholar
• Gould IM, David MZ, Esposito S, et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents. 2012;39:96–104.
   PubMed Web of Science ®Google Scholar
• Nguyen HM, Graber CJ. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother. 2009;65:24–36.
   Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):285-292.
   Google Scholar
• Stryjewski ME, Corey GR. New treatments for methicillin-resistant Staphylococcus aureus. Curr Opin Crit Care. 2009;15:403–412.
   PubMed Web of Science ®Google Scholar
• Vancomycin: a 50-something-year-old antibiotic we still don’t understand. p. 465–471.
   Google Scholar
• Gu B, Kelesidis T, Tsiodras S, et al. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2013;68:4–11.
   PubMed Web of Science ®Google Scholar
• García MS, De La Torre MÁ, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. J Am Med Assoc. 2010;303:2260–2264.
   PubMed Web of Science ®Google Scholar
• Daptomycin: a novel cyclic lipopeptide antimicrobial. p. 1145–1158.
   Google Scholar
• New insights into meticillin-resistant Staphylococcus aureus pathogenesis, treatment and resistance. p. 96–104.
   Google Scholar
• Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11:834–844.
   PubMed Web of Science ®Google Scholar
• Shirley DAT, Heil EL, Johnson JK. Ceftaroline fosamil: a brief clinical review. Infect Dis Ther. 2013;2:95–110.
   PubMedGoogle Scholar
• Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant staphylococcus aureus bloodstream infection. Open Forum infectious Diseases. 2014;9(3). DOI:10.1093/ofid/ofab606.
   Google Scholar
• Echols RM. Understanding the regulatory hurdles for antibacterial drug development in the post-ketek world. Ann N Y Acad Sci. 2011;1241(1):153–161.
   PubMedGoogle Scholar
• Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011;1241(1):48–70.
   PubMedGoogle Scholar
• Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943–950.
   PubMed Web of Science ®Google Scholar
• Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8(6):423–435.
   PubMed Web of Science ®Google Scholar
• Goodman KE, Simner PJ, Tamma PD, et al. Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE). Expert Rev Anti Infect Ther. 2016;14(1):95–108.
   PubMed Web of Science ®Google Scholar
• Sheu CC, Chang YT, Lin SY, et al. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:10.
   PubMed Web of Science ®Google Scholar
• P M, T PT, A A, et al. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother. 2008;61(1):59–63.
   PubMed Web of Science ®Google Scholar
• Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597–602.
   PubMed Web of Science ®Google Scholar
• Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP, et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013;19(2):E72–9.
   PubMed Web of Science ®Google Scholar
• C A, G M, F D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19(1):E23–E30.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future microbiology. 2011;6(6):653–666.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37(5):415–419.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, ampC-, and carbapenemase-producing enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079-17.
   Web of Science ®Google Scholar
• Ku YH, Chen CC, Lee MF, et al. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance. J Microbiol Immunol Infect. 2017;50(6):931–939.
   PubMedGoogle Scholar
• Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(6):3002.
   PubMed Web of Science ®Google Scholar
• Isler B, Doi Y, Bonomo RA, et al. New treatment options against carbapenem-resistant acinetobacter baumannii infections. Antimicrob Agents Chemother. 2019;63(1):e01110-18.
   Google Scholar
• Abbott I, Cerqueira GM, Bhuiyan S, et al. Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies. Expert Rev Anti Infect Ther. 2013;11(4):395–409.
   PubMed Web of Science ®Google Scholar
• Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant acinetobacter baumannii infections. Drugs. 2014;74(12):1315–1333.
   PubMed Web of Science ®Google Scholar
• Piperaki ET, Tzouvelekis LS, Miriagou V, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25(8):951–957.
   PubMed Web of Science ®Google Scholar
• Routsi C, Kokkoris S, Douka E, et al. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents. 2015;45(1):90–93.
   PubMed Web of Science ®Google Scholar
• Greig SL, Scott LJ. Intravenous minocycline: a review in acinetobacter infections. Drugs. 2016;76(15):1467–1476.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vardakas KZ, Roussos NS. Trimethoprim/sulfamethoxazole for acinetobacter spp.: a review of current microbiological and clinical evidence. Int J Antimicrob Agents. 2015;46(3):231–241.
   PubMed Web of Science ®Google Scholar
• Levy SB, Bonnie M. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004;10(S12):S122–S129.
   PubMed Web of Science ®Google Scholar
• Kubiczek D, Raber H, Gonzalez-García M, et al. Derivates of the antifungal peptide Cm-p5 inhibit development of candida auris biofilms in vitro. Antibiot. 2020;9(7):363.
   Google Scholar
• Shaban S, Patel M, Ahmad A. Improved efficacy of antifungal drugs in combination with monoterpene phenols against Candida auris. Sci Rep. 2020;10:1–8.
   PubMed Web of Science ®Google Scholar
• Chami N, Bennis S, Chami F, et al. Study of anticandidal activity of carvacrol and eugenol in vitro and in vivo. Oral Microbiol Immunol. 2005;20(2):106–111.
   PubMedGoogle Scholar
• Ahmad A, Khan A, Akhtar F, et al. Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against Candida. Eur J Clin Microbiol Infect Dis. 2011;30(1):41–50.
   PubMed Web of Science ®Google Scholar
• Sebaa S, Hizette N, Boucherit-Otmani Z, et al. Dose-dependent effect of lysozyme upon Candida albicans biofilm. Mol Med Rep. 2017;15(3):1135–1142.
   PubMed Web of Science ®Google Scholar
• Van Duin D, Kaye KS, Neuner EA, et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75(2):115–120.
   PubMed Web of Science ®Google Scholar
• AK M, Pg A, TH G, et al. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005;52(3):165–171.
   PubMed Web of Science ®Google Scholar
• E A, H KM, H AM, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2009;53(10):4504–4507.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Nichol K, Zhanel GG. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clin Infect Dis. 2015;61(suppl 2):S58–S68.
   PubMed Web of Science ®Google Scholar
• Choo EJ, Chambers HF. Treatment of methicillin-resistant Staphylococcus aureus bacteremia. Infect Chemother. 2016;48(4):267–273.
   PubMed Web of Science ®Google Scholar
• DJ F, RK F, HS S, et al. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother. 2013;57(12):6305–6310.
   PubMed Web of Science ®Google Scholar
• Mangion IK, Ruck RT, Rivera N, et al. A concise synthesis of a β-lactamase inhibitor. Org Lett. 2011;13:5480–5483.
   PubMed Web of Science ®Google Scholar
• Chai J, Lee CH. Management of primary and recurrent clostridium difficile infection: an update. Antibiotics. 2018;7(3):1–8.
   Google Scholar
• Nair DVT, Venkitanarayanan K, Johny AK. Antibiotic-resistant Salmonella in the food supply and the potential role of antibiotic alternatives for control. Foods. 2018;7(10):167.
   Web of Science ®Google Scholar
• Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs. 2012;62(3):425–441.
   Google Scholar
• Norris JRPE AH, Reilly JP, Edelstein PH. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis. 1995;20(5):1137–1144.
   PubMed Web of Science ®Google Scholar
• JR A, MJ R. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob Agents Chemother. 1998;42(9):2188–2192.
   PubMed Web of Science ®Google Scholar
• McNeil NCPC SA. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin). Clin Infect Dis. 2000;30(2):403–404.
   PubMed Web of Science ®Google Scholar
• Abadi ATB. Helicobacter pylori: emergence of a Superbug. Front Med. 2014;1:1–1.
   Google Scholar
• Agudo S, Perez-Perez G, Alarcon T, et al. High prevalence of clarithromycin-resistant helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol. 2010;48(10):3703–3707.
   PubMed Web of Science ®Google Scholar
• Chen D, Cunningham SA, Cole NC, et al. Phenotypic and molecular antimicrobial susceptibility of Helicobacter pylori. Antimicrob Agents Chemother. 2017;61(4):e02530-16.
   Web of Science ®Google Scholar
• Hu Y, Zhang M, Lu B, et al. Helicobacter pylori and antibiotic resistance, A continuing and intractable problem. Helicobacter. 2016;21:349–363.
   PubMed Web of Science ®Google Scholar
• JP Q, EJ D, CA D, et al. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis. 1986;154(2):289–294.
   PubMed Web of Science ®Google Scholar
• Köhler T, Michea-Hamzehpour M, Epp SF, et al. Carbapenem activities against pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother. 1999;43(2):424–427.
   PubMed Web of Science ®Google Scholar
• Huband MD, Castanheira M, Flamm RK, et al. In vitro activity of ceftazidime-avibactam against contemporary Pseudomonas aeruginosa isolates from U.S. Medical centers by Census Region, 2014. Antimicrob Agents Chemother. 2016;60(4):2537–2541.
   PubMed Web of Science ®Google Scholar
• Lolans K, Queenan AM, Bush K, et al. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne Metallo-β-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother. 2005;49(8):3538–3540.
   PubMed Web of Science ®Google Scholar
• Tran TB, Velkov T, Nation RL, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016;48(6):592–597.
   PubMed Web of Science ®Google Scholar
• Zusman O, Altunin S, Koppel F, et al. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(1):29–39.
   PubMed Web of Science ®Google Scholar
• Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother. 2017;61(10):e00875-17.
   Web of Science ®Google Scholar
• YM W, G-Q KE, AN S, et al. Activity of Ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob Agents Chemother. 2017;62(1):e01970-17.
   Web of Science ®Google Scholar
• Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007;51(3):826–830.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Bassetti M, Duncan LR, et al. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob Chemother. 2017;72(5):1386–1395.
   PubMed Web of Science ®Google Scholar
• DM L, W M, M S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286–2290.
   PubMed Web of Science ®Google Scholar
• Smith JL, Fratamico PM. Fluoroquinolone resistance in campylobacter. J Food Prot. 2010;73(6):1141–1152.
   PubMed Web of Science ®Google Scholar
• Mathew AG, Cissell R, Liamthong S. Antibiotic resistance in bacteria associated with food animals: a United States perspective of livestock production. Foodborne Pathog Dis. 2007;4(2):115–133.
   PubMed Web of Science ®Google Scholar
• Pinto M, Matias R, Rodrigues JC, et al. Cephalosporin-resistant neisseria gonorrhoeae isolated in Portugal, 2019. Sex Transm Dis. 2020;47(11):e54–e56.
   PubMedGoogle Scholar
• Ross JDC, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect. 2012;88(1):6–8.
   PubMed Web of Science ®Google Scholar
• Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003;16(3):430–450.
   PubMed Web of Science ®Google Scholar
• Burckhardt MHI, Burckhardt I. In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae. Infect Drug Resist. 2019;12:1889.
   PubMed Web of Science ®Google Scholar
• RF J. Imipenem-cilastatin: the first thienamycin antibiotic. Pediatr Infect Dis. 1986;62(Suppl_2):75-77.
   Google Scholar
• Hikida M, Kawashima K, Yoshida M, et al. Inactivation of new carbapenem antibiotics by dehydropeptidase-i from porcine and human renal cortex. J Antimicrob Chemother. 1992;30(2):129–134.
   PubMed Web of Science ®Google Scholar
• Hori Y, Aoki N, Kuwahara S, et al. Megalin blockade with cilastatin suppresses drug-induced nephrotoxicity. J Am Soc Nephrol. 2017;28(6):1783–1791.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Mavroudis AD, Vardakas KZ. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect? Expert Rev Anti Infect Ther. 2016;14(8):747–763.
   PubMed Web of Science ®Google Scholar
• Blizzard TA, Chen H, Kim S, et al. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. Bioorganic Med Chem Lett. 2014;24(3):780–785.
   PubMed Web of Science ®Google Scholar
• Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60(10):6234–6243.
   PubMed Web of Science ®Google Scholar
• Domalaon R, Idowu T, Zhanel GG, et al. Antibiotic hybrids: the next generation of agents and adjuvants against gram-negative pathogens? Clin Microbiol Rev. 2018;31(2):e00077-17.
   Web of Science ®Google Scholar